Navigation Links
SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
Date:6/9/2008

SAN DIEGO, June 9 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has established a distribution partnership for the Italian market through Medimar Italia, a Milan-based firm specializing in medical device sales in the country.

Michel Vaudry, SpectraScience's Director of International Sales commented that, "We are pleased to have added our second European distributor in the past two months. Medimar is a respected and well-established medical device distributor and its decision to add the WavSTAT Optical Biopsy System to their portfolio is a strong validation of our technology."

Medimar's President, Francesco Torelli, stated that, "SpectraScience's WavSTAT cancer diagnosis system has tremendous potential to impact the marketplace here in Italy. The importance of earlier and more effective screening for colon cancer cannot be stressed enough and we look forward to representing the product and working with SpectraScience to establish and build a strong Italian market presence."

Vaudry added that, "Mr. Torelli is a respected thought leader in the medical device market in Italy, so his support of the WavSTAT System will be instrumental in our acceptance into the major gastroenterology centers in the country."
Key Benefits to the WavSTAT Optical Biopsy System

-- Helps the physician discern between normal and pre-cancerous tissue in

the GI tract

-- Gives the physician additional information that allows for a more

informed decision on leaving polyps on site if they are not

pre-cancerous thereby minimizing risks and time.

-- Provides the opportunity for physicians to perform a physical biopsy at

exactly the same site and time that the optical biopsy is performed

-- Allows physicians to determine the margin, or border of the

pre-cancerous tissue

-- Aids physicians during colon cancer surgery to determine if all

cancerous tissue has been removed

-- Is complementary to NBI and Smart Pill and other recent evaluating

technologies (e.g. Olympus, Pentax, Fujinon, Given).

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward- looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA(R) cervical imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available today.

Contact:

SpectraScience, Inc.

Jim Hitchin, Chief Executive Officer

(858) 847-0200 x201

http://www.spectrascience.com

Hayden Communications

Investor Relations

Todd Pitcher

(858) 518-1387


'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
6. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
7. UI licensee Optherion secures $37 million in financing
8. IPS Secures National Contract to Deliver FOCUS Healthcare Provider Network Access to Pain Management Specialists
9. Piedmont Pharmaceuticals Secures $8.5 Million Investment
10. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
11. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... (PRWEB) , ... December 02, 2016 , ... ... will give patients better access to nutraceuticals and help doctors more efficiently manage ... patient portal and practice management software platform for Integrative and Functional Medicine. ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & ... & Anti-Aging Medicine European Congress (AMEC) brings together the industry’s leading scientific ...
(Date:12/4/2016)... ... December 04, 2016 , ... Are You Concerned About Mold ... certified and experienced Indoor Air Quality Companies in VA, MD and DC, recently completed ... , The new mold law in the district of Columbia is a good ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... documentary on the perils of heroin that was watched live by 1 million ... Alfred I. duPont-Columbia University Award. , ASU students at the Walter Cronkite School ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... Taiwan , Dec. 5, 2016 ... non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... profile of ropeginterferon alfa-2b versus HU AOP ... follow-up trial CONTINUATION-PV to obtain European marketing authorization in the ... data to the FDA as it seeks approval for commercialization ...
(Date:12/4/2016)... --  Pairnomix, LLC, a genetic research company and member ... White House, today announced that findings from its first case ... therapies for a patient with epileptic encephalopathy caused by a ... the 70 th Annual Meeting of the American ... December 2-6, 2016.  Pairnomix, unique process involves creating ...
Breaking Medicine Technology: